Company Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States.
The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy.
It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids.
The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy.
Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| IPO Date | Jan 26, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 88 |
| CEO | Alexander G. Cumbo |
Contact Details
Address: 141 Portland Street Cambridge, Massachusetts United States | |
| Website | https://www.solidbio.com |
Stock Details
| Ticker Symbol | SLDB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001707502 |
| CUSIP Number | 83422E105 |
| ISIN Number | US83422E2046 |
| Employer ID | 90-0943402 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Alexander G. Cumbo | President, Chief Executive Officer & Director |
| Ilan Ganot | Co-founder, Strategic Advisor to the Chief Executive Officer & Director |
| David Tyronne Howton Jr., J.D. | Chief Operating Officer, General Counsel & Secretary |
| Kevin Tan C.F.A. | Chief Financial Officer & Treasurer |
| Paul Herzich | Chief Technology Officer |
| Allison Bogosian J.D. | Senior Vice President of Human Resources |
| Annie Ganot | Co-Founder & Head of Patient Advocacy |
| Dr. Jessie Hanrahan Ph.D. | Chief Regulatory Officer |
| Dr. Shuli Kulak M.D. | Head of Corporate Strategy & Business Development |
| Ian F. Smith A.C.A., C.P.A. | Executive Chair |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 04, 2024 | 4 | Filing |
| Dec 04, 2024 | 4 | Filing |
| Dec 04, 2024 | 4 | Filing |
| Dec 04, 2024 | 4 | Filing |
| Nov 19, 2024 | 4 | Filing |
| Nov 19, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13D/A | [Amend] Filing |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |